Provectus slammed in early trading

|About: Provectus Biopharmaceu... (PVCT)|By:, SA News Editor

Investors lack enthusiasm for shares of Provectus Biopharmaceuticals (PVCT -65.3%) today in apparent response to the FDA's thumbs down regarding its BTD application for PV-10. The agency cites the lack of data demonstrating that PV-10 is substantially better than existing therapies. Shares plummet on a 3x surge in volume.

Despite the setback, the company still plans to commercialize the product.